Goldman Sachs has beaten rivals JP Morgan and Lehman Brothers to a mandate to sell the $800m (€606m) consumer medicines unit of Bristol-Myers Squibb, the US pharmaceuticals giant.

According to a report on Bloomberg, citing unnamed people familiar with the situation, Goldman will sell the business to leave Bristol-Myers to focus on its core pharmaceuticals business.